Baxter Posts Wider 4Q Loss, Says Results Missed Expectations

Dow Jones

Feb 12

By Nicholas G. Miller

Baxter International reported a wider fourth-quarter loss and said that despite sales growth across categories, the quarter's results missed its expectations.

Shares fell 15% to $19.02 in premarket trading.

The healthcare company reported a wider loss of $1.13 billion, or $2.19 a share, compared with a loss of $512 million, or $1 a share, the year prior. The loss included a goodwill impairment charge of $485 million related to the Front Line Care reporting unit.

Adjusted earnings were 36 cents a share. The company said adjusted profit was hurt by unfavorable product mix, non-recurring items including inventory adjustments and a higher effective tax rate.

Sales from continuing operations rose 8% to $2.97 billion. Medical products and therapies revenue rose 6%, healthcare systems and technologies sales increased 5%, while pharmaceutical sales rose 4%.

"While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations," said Chief Executive Andrew Hider.

The company guided for 2026 sales from continuing operations to be flat to up 1% and adjusted earnings from continuing operations of $1.85 to $2.05 a share.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

February 12, 2026 07:50 ET (12:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610926119"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610926119\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610926119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610926119","market":"us","top_or_hot":-1,"title":"Baxter Posts Wider 4Q Loss, Says Results Missed Expectations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Baxter International reported a wider fourth-quarter loss and said that despite sales growth across categories, the quarter's results missed its expectations. \n</p>\n<p>\n  Shares fell 15% to $19.02 in premarket trading. \n</p>\n<p>\n  The healthcare company reported a wider loss of $1.13 billion, or $2.19 a share, compared with a loss of $512 million, or $1 a share, the year prior. The loss included a goodwill impairment charge of $485 million related to the Front Line Care reporting unit. \n</p>\n<p>\n  Adjusted earnings were 36 cents a share. The company said adjusted profit was hurt by unfavorable product mix, non-recurring items including inventory adjustments and a higher effective tax rate. \n</p>\n<p>\n  Sales from continuing operations rose 8% to $2.97 billion. Medical products and therapies revenue rose 6%, healthcare systems and technologies sales increased 5%, while pharmaceutical sales rose 4%. \n</p>\n<p>\n  \"While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations,\" said Chief Executive Andrew Hider. \n</p>\n<p>\n  The company guided for 2026 sales from continuing operations to be flat to up 1% and adjusted earnings from continuing operations of $1.85 to $2.05 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2026 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baxter Posts Wider 4Q Loss, Says Results Missed Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaxter Posts Wider 4Q Loss, Says Results Missed Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-12 20:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Baxter International reported a wider fourth-quarter loss and said that despite sales growth across categories, the quarter's results missed its expectations. \n</p>\n<p>\n  Shares fell 15% to $19.02 in premarket trading. \n</p>\n<p>\n  The healthcare company reported a wider loss of $1.13 billion, or $2.19 a share, compared with a loss of $512 million, or $1 a share, the year prior. The loss included a goodwill impairment charge of $485 million related to the Front Line Care reporting unit. \n</p>\n<p>\n  Adjusted earnings were 36 cents a share. The company said adjusted profit was hurt by unfavorable product mix, non-recurring items including inventory adjustments and a higher effective tax rate. \n</p>\n<p>\n  Sales from continuing operations rose 8% to $2.97 billion. Medical products and therapies revenue rose 6%, healthcare systems and technologies sales increased 5%, while pharmaceutical sales rose 4%. \n</p>\n<p>\n  \"While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations,\" said Chief Executive Andrew Hider. \n</p>\n<p>\n  The company guided for 2026 sales from continuing operations to be flat to up 1% and adjusted earnings from continuing operations of $1.85 to $2.05 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2026 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610926119","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610926119","pubTimestamp":1770900600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Baxter International reported a wider fourth-quarter loss and said that despite sales growth across categories, the quarter's results missed its expectations.Shares fell 15% to $19.02 in premarket trading.The healthcare company reported a wider loss of $1.13 billion, or $2.19 a share, compared with a loss of $512 million, or $1 a share, the year prior. The loss included a goodwill impairment charge of $485 million related to the Front Line Care reporting unit.Adjusted earnings were 36 cents a share. The company said adjusted profit was hurt by unfavorable product mix, non-recurring items including inventory adjustments and a higher effective tax rate.Sales from continuing operations rose 8% to $2.97 billion. Medical products and therapies revenue rose 6%, healthcare systems and technologies sales increased 5%, while pharmaceutical sales rose 4%.\"While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations,\" said Chief Executive Andrew Hi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4588":"碎股","BK4082":"医疗保健设备","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4504":"桥水持仓","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BAX":"百特国际","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD"},"translate_title":"百特第四季度亏损扩大，称业绩未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAX":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Baxter International reported a wider fourth-quarter loss and said that despite sales growth across categories, the quarter's results missed its expectations. \n\n\n  Shares fell 15% to $19.02 in premarket trading. \n\n\n  The healthcare company reported a wider loss of $1.13 billion, or $2.19 a share, compared with a loss of $512 million, or $1 a share, the year prior. The loss included a goodwill impairment charge of $485 million related to the Front Line Care reporting unit. \n\n\n  Adjusted earnings were 36 cents a share. The company said adjusted profit was hurt by unfavorable product mix, non-recurring items including inventory adjustments and a higher effective tax rate. \n\n\n  Sales from continuing operations rose 8% to $2.97 billion. Medical products and therapies revenue rose 6%, healthcare systems and technologies sales increased 5%, while pharmaceutical sales rose 4%. \n\n\n  \"While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations,\" said Chief Executive Andrew Hider. \n\n\n  The company guided for 2026 sales from continuing operations to be flat to up 1% and adjusted earnings from continuing operations of $1.85 to $2.05 a share. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2026 07:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}